What this deck covers
This deck focuses on Immunization And Prevention Programs, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Immunization And Prevention Programs in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
Which meningococcal vaccine type is indicated for serogroup B disease prevention: MenACWY or MenB?
Tap card or press Space to flip
MenB vaccine. MenB targets serogroup B capsular polysaccharides, addressing strains not covered by quadrivalent vaccines.
How well did you know it?
Card 1 / 25
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Immunization And Prevention Programs, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: MenB vaccine. MenB targets serogroup B capsular polysaccharides, addressing strains not covered by quadrivalent vaccines.
Answer: IM injection in the deltoid muscle. The deltoid muscle offers sufficient mass and accessibility, minimizing risks like nerve damage for IM vaccine delivery in adults.
Answer: Anaphylaxis to a prior dose or vaccine component. Severe allergic reactions indicate hypersensitivity, posing a life-threatening risk upon re-exposure.
Answer: IM injection in the anterolateral thigh (vastus lateralis). The vastus lateralis provides the largest muscle mass in infants, reducing the risk of hitting nerves or blood vessels.
Answer: Needle length typically 1 inch (adjust for body habitus). A 1-inch needle penetrates the deltoid muscle adequately in average adults, with adjustments ensuring proper depth based on subcutaneous fat.
Answer: Hepatitis A vaccine as postexposure prophylaxis (IG for select cases). Vaccine induces active immunity effectively for postexposure prophylaxis, with IG reserved for high-risk or contraindicated individuals.
Answer: Vaccine Information Statement (VIS). VIS ensures patients receive standardized, understandable information on vaccine benefits, risks, and alternatives as required by law.
Answer: Do not restart; continue the series using minimum intervals. Resuming the series maintains protective immunity without wasting prior doses, using minimum intervals to complete it efficiently.
Answer: Two doses for adults aged 50 years and older. This regimen boosts cell-mediated immunity against varicella-zoster virus, reducing shingles risk in aging populations.
Answer: Use caution; generally avoid if GBS occurred within 6 weeks of a flu vaccine. Prior GBS post-vaccination suggests potential recurrence risk, warranting avoidance unless benefits outweigh risks.
Answer: MMR within 72 hours or immune globulin within 6 days. Timely MMR stimulates active immunity to prevent infection, while IG offers passive protection if the vaccine window is missed.
Answer: PPSV23 is polysaccharide; PCV vaccines are conjugate. PPSV23 consists of purified capsular polysaccharides, eliciting a T-cell independent response, unlike protein-conjugated PCV vaccines.
Answer: Universal hepatitis B vaccination for ages 19 to 59 years. This policy aims to reduce hepatitis B transmission by vaccinating all in this age group without risk assessment.
Answer: High-dose or adjuvanted inactivated influenza vaccine. These formulations enhance immunogenicity to overcome age-related immune decline in older adults.
Answer: Repeat the second live vaccine at least 28 days after the first. Insufficient spacing can cause immune interference from the first vaccine, rendering the second dose ineffective.
Answer: Observe the patient seated or supine for about 15 minutes. This positioning and observation period prevents injury from falls and monitors for complications post-vasovagal reaction.
Answer: Live attenuated vaccines are contraindicated in pregnancy. These vaccines contain replicating organisms that pose a theoretical risk of infection to the fetus.
Answer: Td or Tdap every 10 years. Decennial boosters sustain protective antitoxin levels against tetanus and diphtheria in adults.
Answer: Do not repeat dose if valid; document and counsel (repeat only if clearly invalid). Many inactivated vaccines remain immunogenic via subcutaneous route, avoiding unnecessary revaccination unless efficacy is compromised.
Answer: Any clinically significant adverse event after vaccination. VAERS tracks any notable health issues post-vaccination to identify potential safety signals, regardless of causality.
Answer: Intranasal administration. Intranasal delivery enables the attenuated virus to replicate in the upper respiratory tract, stimulating local mucosal immunity against influenza.
Answer: At least 2 months (typically given at 0 and 2 to 6 months). This spacing optimizes the adjuvant-enhanced immune response for long-term protection against herpes zoster.
Answer: Heplisav-B: 2 doses separated by at least 4 weeks. Its adjuvanted formulation achieves high seroprotection with fewer doses compared to traditional 3-dose series.
Answer: ZVL (Zostavax) is live; RZV is nonlive recombinant. Live attenuated vaccines can replicate and cause disease in those with impaired immunity, unlike nonlive options.
Answer: Tdap during each pregnancy. Tdap during pregnancy transfers maternal antibodies to the infant, protecting against pertussis in early infancy.